CA2859227C - Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions - Google Patents

Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions Download PDF

Info

Publication number
CA2859227C
CA2859227C CA2859227A CA2859227A CA2859227C CA 2859227 C CA2859227 C CA 2859227C CA 2859227 A CA2859227 A CA 2859227A CA 2859227 A CA2859227 A CA 2859227A CA 2859227 C CA2859227 C CA 2859227C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
polar solvent
amyloid
isoacteoside
acteoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859227A
Other languages
English (en)
French (fr)
Other versions
CA2859227A1 (en
Inventor
Hang-Ching Lin
Muh-Hwan Su
Young-Ming Huang
Jing-jing TANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinphar Tian Li Pharmaceutical Co Ltd
Original Assignee
Sinphar Tian Li Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinphar Tian Li Pharmaceutical Co Ltd filed Critical Sinphar Tian Li Pharmaceutical Co Ltd
Publication of CA2859227A1 publication Critical patent/CA2859227A1/en
Application granted granted Critical
Publication of CA2859227C publication Critical patent/CA2859227C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2859227A 2011-12-16 2012-12-17 Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions Active CA2859227C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576367P 2011-12-16 2011-12-16
US61/576,367 2011-12-16
PCT/CN2012/086796 WO2013087042A1 (zh) 2011-12-16 2012-12-17 预防或治疗淀粉样β肽相关疾病或状况的医药组合物

Publications (2)

Publication Number Publication Date
CA2859227A1 CA2859227A1 (en) 2013-06-20
CA2859227C true CA2859227C (en) 2019-01-22

Family

ID=48580733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859227A Active CA2859227C (en) 2011-12-16 2012-12-17 Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions

Country Status (11)

Country Link
US (1) US20150087606A1 (https=)
EP (1) EP2792361B1 (https=)
JP (1) JP6134331B2 (https=)
KR (1) KR102048289B1 (https=)
CN (1) CN103156867B (https=)
AU (1) AU2012350437B2 (https=)
CA (1) CA2859227C (https=)
MY (1) MY171048A (https=)
SG (1) SG11201403265VA (https=)
TW (1) TWI488630B (https=)
WO (1) WO2013087042A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154721A1 (zh) * 2014-04-10 2015-10-15 杏辉天力（杭州）药业有限公司 异类叶升麻苷衍生物及其制造方法与用途
TWI650131B (zh) 2014-07-03 2019-02-11 杏輝藥品工業股份有限公司 管花肉蓯蓉萃取物之用於製備保護眼部細胞之藥品或食品用途
CN104922137B (zh) * 2015-06-04 2018-07-31 苏州大学 苯乙醇苷类化合物Torenoside B的新用途
KR102018085B1 (ko) * 2017-12-06 2019-09-04 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR102135148B1 (ko) * 2019-08-28 2020-07-20 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
CN110812375A (zh) * 2019-12-12 2020-02-21 中国海洋大学 一种老鼠簕中苯乙醇苷类提取物及其制备方法与作为抗肝损伤药物的应用
CN111632058A (zh) * 2020-06-24 2020-09-08 新疆医科大学 毛蕊花糖苷在制备预防和治疗神经退行性疾病药物中的应用
CN112225766A (zh) * 2020-10-27 2021-01-15 杏辉天力（杭州）药业有限公司 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100500584B1 (ko) * 2002-08-12 2005-07-12 경희대학교 산학협력단 신경성장인자와 유사 작용을 갖는 육종용 추출물 및 이를함유하는 조성물
KR100514076B1 (ko) * 2003-01-10 2005-09-13 주식회사 엘컴사이언스 페닐에타노이드 유도체를 포함하는 퇴행성 뇌신경계질환의 예방 및 치료용 조성물
TW200416036A (en) * 2003-02-18 2004-09-01 Sinphar Pharmaceutical Co Ltd Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same
CN1268341C (zh) * 2003-03-04 2006-08-09 杏辉天力（杭州）药业有限公司 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途
CN100345857C (zh) * 2004-07-16 2007-10-31 北京华医神农医药科技有限公司 一种从肉苁蓉药材中提取、分离松果菊苷的方法
EP1736167B1 (en) * 2005-06-20 2018-03-21 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use
JP5410683B2 (ja) 2008-02-19 2014-02-05 学校法人近畿大学 カンカニクジュヨウから得られる肝保護剤及び抗ＴＮＦ−α作用剤
CN101411753B (zh) * 2008-12-04 2012-02-29 闫明 列当总苷在制备抗老年痴呆的药物中的应用
CN101797307B (zh) * 2010-04-09 2011-08-10 广州中医药大学 一种含苯乙醇苷的枇杷叶紫珠提取物及其制备方法
TWI486162B (zh) * 2010-06-16 2015-06-01 Sinphar Pharmaceutical Co Ltd 異類葉升麻苷或其醫藥學上可接受之鹽於抑制澱粉樣β肽生成、累積或聚集、以及製備預防或治療澱粉樣β肽相關疾病或狀況的藥物之用途
CN102670631B (zh) * 2011-12-01 2013-07-31 河南科技大学 一种四楞麻总苯乙醇苷组合物、制备方法及应用

Also Published As

Publication number Publication date
EP2792361A4 (en) 2015-05-13
EP2792361B1 (en) 2019-03-27
AU2012350437B2 (en) 2017-06-29
KR20150002576A (ko) 2015-01-07
CA2859227A1 (en) 2013-06-20
MY171048A (en) 2019-09-23
TWI488630B (zh) 2015-06-21
JP6134331B2 (ja) 2017-05-24
JP2015500300A (ja) 2015-01-05
CN103156867B (zh) 2019-04-30
EP2792361A1 (en) 2014-10-22
CN103156867A (zh) 2013-06-19
SG11201403265VA (en) 2014-09-26
TW201325597A (zh) 2013-07-01
AU2012350437A1 (en) 2014-07-31
KR102048289B1 (ko) 2020-01-08
US20150087606A1 (en) 2015-03-26
WO2013087042A1 (zh) 2013-06-20

Similar Documents

Publication Publication Date Title
CA2859227C (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2013173129A3 (en) Treatment of amd using aav sflt-1
JP2015500300A5 (https=)
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
CN105592852B (zh) 肥胖抑制组合物
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
WO2014167584A3 (en) Herbal compositions for treating pain and skin disorders
HK1206347A1 (en) Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
CN105012279B (zh) 含奇壬醇的组合物及其在医药上的应用
CN103721148B (zh) 一种治疗急慢性胃肠炎的益智仁组合物及其制备方法
GB201117490D0 (en) Anti-inflammatory compounds
CN100496529C (zh) 一种利用蒺藜全草提取蒺藜总皂苷的工艺
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
Zhang et al. Advances regarding the mechanism of endoplasmic reticulum stress in diabetic kidney disease and pharmacological interventions
WO2017119416A1 (ja) 黄杞葉又は黄杞葉抽出物を有効成分として含むシノビオリンの活性阻害剤
Ayo et al. Cytotoxicity and antimicrobial studies of 1, 6, 8-trihydroxy-3-methyl-anthraquinone (emodin) isolated from the leaves of Cassia nigricans Vahl
KR20120108384A (ko) 파낙사디올계 진세노사이드와 파낙사트리올계 진세노사이드를 분리하는 방법
CN102727542A (zh) 一种消肿止痛软膏剂
Zhou et al. Protopanaxadiol saponins in the caudexes and leaves of panax notoginseng could be the main constituents that contribute to its antidepressant effects
Teng et al. 7, 8-Dihydroxyflavone: Sources, Pharmacokinetics, Bioavailability, and Biological Effects
Zhu et al. CHEMICAL CONSTITUTES FROM THE RHIZOMES OF MATTEUCCIA ORIENTALIS AND THEIR ANTIOXIDANT ACTIVITY
CN102949469B (zh) 唐松草提取物制备治疗老年痴呆症药物的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160805

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202